Sandeep Arora

Sandeep Arora

Auto-generated profile, based on publicly available information

Sandeep Arora

Chitkara College of Pharmacy, Chitkara University, Punjab, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2020 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DLDamanpreet Kaur Lang
Damanpreet Kaur Lang
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
RARashmi Arora
Rashmi Arora
BSBalraj Saini
Balraj Saini
SASandeep Arora
Sandeep Arora
Background: Cancer is spreading all over the world, and it is becoming the leading cause of major deaths. Today’s most difficult task for every researcher is to invent a new drug that can treat cancer with minimal side effects. Many factors, including pollution, modern lifestyle and food habits, exposure to oncogenic agents or radiations, enhanced industrialization, etc. can cause cancer. Treatment of cancer is done by various methods that include chemotherapy, radiotherapy, surgery and immunotherapy in combination or singly along with kinase inhibitors. Most of the anti-cancer drugs use the concept of kinase inhibition. Objective: The number of drugs being used in chemotherapy has heterocycles as their basic structure in spite of various side effects. Medicinal chemists are focusing on nitrogen-containing heterocyclic compounds like pyrrole, pyrrolidine, pyridine, imidazole, pyrimidines, pyrazole, indole, quinoline, oxadiazole, azole, benzimidazole, etc. as the key building blocks to develop active biological compounds. The aim of this study is to attempt to compile a dataset of nitrogen-containing heterocyclic anti-cancer drugs. Methods: We adopted a structural search on notorious journal publication websites and electronic databases such as Bentham Science, Science Direct, PubMed, Scopus, USFDA, etc. for the collection of peer-reviewed research and review articles for the present review. The quality papers were retrieved, studied, categorized into different sections, analyzed and used for article writing. Conclusion: As per FDA databases, nitrogen-based heterocycles in the drug design are almost 60% of unique small-molecule drugs. Some of the nitrogen-containing heterocyclic anti-cancer drugs are Axitinib, Bosutinib, Cediranib, Dasatanib (Sprycel®), Erlotinib (Tarceva®), Gefitinib (Iressa®), Imatinib (Gleevec®), Lapatinib (Tykerb ®), Linifanib, Sorafenib (Nexavar®), Sunitinib (Sutent®), Tivozanib, etc. In the present review, we shall focus on the overview of nitrogen-containing heterocyclic active compounds as anti-cancer agents.

15 April 2021 in Current Bioactive Compounds
Verified
Journal Article
Closed access
PDF file
Rajwinder KaurRajwinder Kaur
Rajwinder Kaur
KKKirandeep Kaur
Kirandeep Kaur
RARashmi Arora
Rashmi Arora
BSBalraj Saini
Balraj Saini
SASandeep Arora
Sandeep Arora
Background: In the last two decades, the flavonoids containing fused heterocyclic nucleus in their chemical structure have emerged to display a variety of pharmacological effects including antiallergic and anti-inflammatory the most recent to the list. These polyphenolic compounds exert their pharmacological effect by various mechanisms including inhibition of human neutrophil elastase, cytokines (Interleukins- IL-3 and IL-4) and mast cells. Methods: We adopted a structured search of notorious journal publication websites and electronic databases such as Science Direct, Bentham, Scopus, PubMed, Nature, Springer etc. for the collection of peer-reviewed research and review articles for the present review. The quality papers (109) were retrieved, studied, categorized into different sections, analyzed and used for article writing. Results: The backbone of this review article is based on four review articles of natural phenolics. Seventeen papers out of total one hundred and nine were about Quercetin the main molecule of interest, five papers outlined the potential benefits of Pycnogenol, Rutin was discussed in detail by considering eight papers in mind, Kaempferol which can be considered as a candidate of interest was referred from six articles. Conclusion: This review identified the Quercetin, Pycnogenol, Rutin and Kampferol as few bioflavonols out of hundreds of other compounds still under clinical trials that have been studied most. Marketed formulations of Pycnogenol are also available as nutraceuticals. These flavonoids have been also reported to the other pharmacological effects like anti-cancer, anti-oxidants, anti-hypertensive, antiviral, anti-ulcerogenic, anti-platelet, anti-hypotensive and anti-hepatotoxic. With all these versatile properties heterocyclic containing flavonoids may be a powerful candidate for the discovery of their utilization in other ailments like asthma.

1 April 2021 in Current Drug Therapy
Verified
Journal Article
Closed access
PDF file
AKAmit Kaushal
Amit Kaushal
SASandeep Arora
Sandeep Arora
NSNeelam Sharma
Neelam Sharma
SSSukhbir Singh
Sukhbir Singh
Objective: Adequate glycemic control in diabetes patients requires oral combination therapy. Saxagliptin is a dipeptidyl peptidase-4 inhibitor having fewer adverse effects, and metformin is the first-line medicine for diabetes treatment. The aim of this research work is to develop a bilayer tablet of saxagliptin and metformin in fixed-dose combination (FDC) using quality by design (QbD) to acquire the immediate release of saxagliptin and sustained release of metformin from bilayer tablet to ultimately achieve superior patient compliance. Methods: The development of the bilayer tablet was done in four stages using QbD. In the first step, quality target product profile (QTPP) of bilayer tablet was defined, and critical quality attributes (CQAs) were identified by risk estimation matrix and taguchi design; an immediate release saxagliptin layer was optimized in the second step, optimization of sustained-release metformin layer was carried out in the third step, and in the final step, bilayer tablet was prepared and characterized. The effect of independent parameters, i.e., magnesium stearate level (X-1), kneading time (X-2) and lubrication time (X-3) on Carr's Index (Y-1), percentage relative standard deviation of content uniformity (Y-2) and drug release at 30 minutes (Y-3), were estimated for optimization of immediate release saxagliptin layer using Box-Behnken design (BBD). The effect of independent parameters, i.e., hydroxypropyl methylcellulose level (X-4), compritol level (X-5) and magnesium stearate level (X-6) on Carr's Index (Y-4), drug release at 2 h (Y-5), drug release at 5 h (Y-6) and drug release at 10 h (Y-7) were estimated for optimization of sustained-release metformin layer using BBD. Results: The optimized composition of immediate release saxagliptin layer estimated using numerical optimization by Design expert was 0.88% (X-1), 15 minutes (X-2) and 3.85 minutes (X-3) with predicted variables, i.e., 10.59% (Y-1), 3.16% (Y-2) and 85% (Y-3). The optimized composition of sustained-release saxagliptin layer predicted through numerical optimization was 30% (X-4), 3.36% (X-5) and 0.9% (X-6) having 10.89% (Y-4), 43.44% (Y-5), 60% (Y-6) and 85.14% (Y-7). In-vitro dissolution study of bilayer tablet showed immediate release of Saxagliptin (approximately 85% in 30 minutes) and sustained release of metformin illustrating 43.21 +/- 1.21, 60.86 +/- 2.96 and 86.26 +/- 1.38% drug release at 2, 5 and 10 h, respectively. The release exponent for the Korsmeyer-Peppas model for Saxagliptin and metformin was 0.237 (0.85), indicating Fickian and super case II transport drug release behavior, respectively. Conclusion: By QbD approach, bilayer tablet containing saxagliptin and metformin was successfully developed, and influence of various formulation parameters on CQAs of drug products was understood with fewer experiments. This leads to the conclusion that cost can be reduced using QbD in the development of FDC for improving patient compliance.

7 January 2022 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
PNPriya Nijhawan
Priya Nijhawan
Tapan BehlTapan Behl
Tapan Behl
SCSridevi Chigurupati
Sridevi Chigurupati
ASAayush Sehgal
Aayush Sehgal
SSSukhbir Singh
Sukhbir Singh
Simona BungăuSimona Bungău
Simona Bungău

7 December 2020 in Alzheimer's & Dementia
Verified
Journal Article
Open access
PDF file
MSManjinder Singh
Manjinder Singh
SASandeep Arora
Sandeep Arora
OSOm Silakari
Om Silakari
Background: Multi‐target compounds comprise a novel class of therapeutic agents for the treatment of multi‐factorial diseases like Alzheimer’s disease (AD). Following this approach, a new series of flavones were designed, synthesized and biologically evaluated against acetylcholinesterase (AChE), advanced glycation end products formation (AGEs) with additional free radical scavenging activity.Method: On the basis of proposed hypothesis, 33 flavone derivatives were designed and subsequently synthesized and were primarily evaluated for in vitro AChE inhibitory, AGEs inhibitory and anti‐oxidative activity and prominent compounds further evaluated by in vivo anti‐amnestic activity. After that, molecular docking and Molecular dynamic simulations (MD) were carried out for the most potent compounds to study protein‐ligand interactions.Result: The in vitro studies showed that the majority of synthesized derivatives inhibited acetylcholinesterase (AChE) with IC50 values in the nanomolar range. Additionally, these compounds also exhibited greater ability to inhibit advanced glycation end products formation in micromolar range with additional radical scavenging property in nanomolar range. The most active compounds were also ameliorated scopolamine‐induced amnesia in mice in terms of restoration of time spent in target quadrant (TSTQ) and escape latency time (ELT). Moreover, the molecular docking study displayed that most potent compounds simultaneously bind to catalytic active site (CAS) and peripheral anionic site (PAS) of AChE.Conclusion: In conclusions, the results support the proposed hypothesis that newly designed multi‐target flavones have the ability to act on different targets or exhibit multiple pharmacological activities related to Alzheimer’s disease. Thus, flavones might be the promising lead compound as potential multi‐target anti‐Alzheimer’s agents.

26 December 2019 in Current Organic Synthesis
Verified
Journal Article
Closed access
PDF file
AGAnkur Gera
Ankur Gera
CMChander Mohan
Chander Mohan
JMJitender Madan
Jitender Madan
SASandeep Arora
Sandeep Arora
Background: Oxidative stress due to high levels of reactive organic species is the cause of the progression of inflammation in various diseases. The molecules possessing both anti-inflammatory and antioxidant activity can be the promising key to treat inflammatory diseases. Phthalimide and hydrazinecarbothioamide are anti-inflammatory and anti-oxidant pharmacophores.Objective: Molecular hybrids possessing above two pharmacophores were designed. A series of N-phenyl substituted 2-(2-(1,3-dioxoisoindolin-2-yl)acetyl)-N-phenylhydrazine-1-carbothioamide (CGS compounds) was synthesized and evaluated for biological activities.Methods: N-phthaloylglycyl hydrazide was reacted with unsubstituted/substituted phenyl isothiocyanates to yield CGS compounds. Synthesized compounds were evaluated for in vivo anti-inflammatory activity in carrageenan rat paw edema model, and in vitro anti-oxidant activity by DPPH assay. Levels of TNF-α and oxidative stress at the site of inflammation were measured. The genetic algorithm-PLS regression based QSAR model correlating the effect of N-phenyl substituent on the anti-inflammatory activity was developed. Further, the interaction of the active compound in the TNF-α binding pocket was studied by in silico docking.Results: Compound containing the 2-OCH3, 4-NO2 (CGS-5); 4-CF3 (CGS-9); 4-NO2 (CGS-3) showed significant anti-inflammatory activity (percentage inhibition of paw edema after 3 hour = 58.24, 50.38, 40.05, respectively) and potent anti-oxidant activity (IC50 =0.045, 0.998, 0.285 μg/ml, respectively). Reduced levels of TNF- α and increased levels of GSH were observed for the above three compounds. Descriptors for QSAR model identified by GA-PLS were WPSA1, Weta1unity, WDunity, SC3, VC5, MlogP, and WTPT3. The identified model was highly predictive, and value of root mean square error of prediction for internal (leave one out) and external validation was: 1.579, 1.325.Conclusion: Molecular hybrids of phthalimide and hydrazinecarbothioamide were synthesized. Some of the compounds possessed promising anti-inflammatory and anti-oxidant activities.